Upadacitinib, a selective JAK1 inhibitor, may impair cellular immunity necessary for HPV clearance, potentially leading to treatment-resistant or persistent condyloma acuminatum. This evidence concerns the gene JAK1 and anogenital human papillomavirus infection.